US Bills Aim To Reduce Pharma Manufacturing Reliance On China
Training, Technologies To Be Boosted
Executive Summary
A US bipartisan Senate bill and House proposal aim to bring pharma manufacturing from China to closer to home, through partnerships with American universities to train the workforce and develop technologies.
You may also be interested in...
US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
China Takes A Bigger Role In The World Pharma Stage
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
China Regulatory Express: Patent Linkage, Data Protection, Bio Five-Year Plan
Important changes are coming to China's Drug Administration Law as the government aims to address through several revisions a number of key issues since the law’s original enactment in 2019.